Balchem closes $332.5M acquisition of Kappa Bioscience, financed via credit facility and cash

BALCHEM CORP

Purchase price ~NOK 3.3B ($332.5M) includes assumption and repayment of NOK 303.5M ($30.6M) of Kappa debt.
Seller eligible for earn-out payment in 2024 of up to ~16% of NOK 3.175B based on growth targets.
Kappa is a leading science-based manufacturer of specialty vitamin K2 for human nutrition.
At Annual Meeting, shareholders elected three Class 1 directors, ratified RSM US LLP as auditor, and approved executive compensation on advisory basis.
Acquisition financed through Balchem's existing revolving credit facility and cash on hand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.